Loring Wolcott & Coolidge Fiduciary Advisors LLP Incyte Corp Transaction History

Loring Wolcott & Coolidge Fiduciary Advisors LLP

$11.1 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 22, 2020	SELL	$73.04 - $95.72 $45,284 - $59,346	-620 Closed	0 $0
Q3 2019 Nov 05, 2019	BUY	$72.82 - $86.52 $45,148 - $53,642	620 New	620 $46,000
Q3 2018 Oct 31, 2018	SELL	$61.75 - $74.23 $35,506 - $42,682	-575 Closed	0 $0
Q2 2018 Aug 07, 2018	SELL	$60.85 - $83.98 $58,720 - $81,040	-965 Reduced 62.66%	575 $39,000
Q1 2018 Apr 20, 2018	BUY	$83.06 - $100.98 $16,695 - $20,296	201 Added 15.01%	1,540 $128,000
Q3 2017 Oct 27, 2017	BUY	$109.15 - $138.27 $1,528 - $1,935	14 Added 1.06%	1,339 $156,000
Q2 2017 Aug 07, 2017	BUY	N/A	1,325	1,325 $0

Others Institutions Holding INCY

# of Institutions

643

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loring Wolcott & Coolidge Fiduciary Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Loring Wolcott & Coolidge Fiduciary Advisors LLP with notifications on news.

Account